Related Experiment Videos
d-Sotalol: a new potent class III anti-arrhythmic agent
Clinical Science (London, England : 1979)
|November 1, 1985
Summary
Dextro-sotalol, a new drug, demonstrated similar Class III anti-arrhythmic action to dl-sotalol in dogs. This suggests d-sotalol may be an effective anti-arrhythmic agent for human use.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
Background:
- Sotalol is a known anti-arrhythmic drug with beta-blocking properties.
- The specific effects of the dextro-isomer (d-sotalol) on cardiac action potential, independent of beta-blockade, require further investigation.
Purpose of the Study:
- To compare the effects of d-sotalol and dl-sotalol on monophasic action potential (MAP) duration in dogs.
- To determine if d-sotalol exhibits Class III anti-arrhythmic activity similar to dl-sotalol.
Main Methods:
- Open-chested dogs were anesthetized and underwent atrioventricular block.
- Doses of d-sotalol and dl-sotalol were administered intravenously after propranolol pre-treatment.
- Monophasic action potentials were recorded from the endocardium and epicardium at paced heart rates of 100 and 150 bpm.
Main Results:
- Both d-sotalol and dl-sotalol significantly prolonged MAP duration at 90% repolarization.
- The prolongation of MAP duration was similar for both compounds in both endocardial and epicardial recordings.
- These effects were observed at both tested heart rates and across a range of doses.
Conclusions:
- Dextro-sotalol exhibits Class III anti-arrhythmic activity comparable to dl-sotalol.
- The Class III action of d-sotalol is homogeneous across left ventricular endocardium and epicardium.
- D-sotalol shows potential as a novel anti-arrhythmic therapeutic agent for human use.